Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy | MicrobiomeTrials← Back to trialsNCT06851767
Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy
ENROLLING_BY_INVITATIONPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-05-09Est. Completion: 2034-12-31
Enrollment target: 18 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
X-linked Severe Combined Immunodeficiency (XSCID)
This is a Phase I/II non-randomized clinical trial of ex vivo hematopoietic stem cell (HSC) gene transfer treatment for …
Bethesda, United StatesEst. completion Dec 31, 2032
Chronic Granulomatous Disease (CGD)X-Linked Severe Combined Immune Deficiency (XSCID)Leukocyte Adhesion Deficiency 1 (LAD)Graft Versus Host Disease (cGvHD)
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chron…
Bethesda, United States